Literature DB >> 28695060

Can levodopa prevent cognitive decline in patients with Parkinson's disease?

Masahiro Ikeda1, Hiroshi Kataoka1, Satoshi Ueno1.   

Abstract

Cognitive impairment in Parkinson's disease (PD) will become more important since the number of elderly patients with PD is increasing. We prospectively studied non-demented patients with PD over the course of 3 years to identify factors associated with PD that contribute to a decline in cognitive function. From among 100 consecutive patients, we registered 79 patients with PD. A total of 55 patients completed the study during 3 years and were divided to two groups: patients with a decline in cognitive function and those without a decline in cognitive function after 3 years. Seventeen independent variables were evaluated with the use of logistic regression models. The increase in the daily levodopa dose was related to a decline in cognitive function on univariate logistic regression analysis (OR = 0.279, p = 0.024, 95% CI = 0.092-0.848). Other variables were not related to a decline in cognitive function. The increase in the daily dose of levodopa was greater in patients without a decline in cognitive function than those with a decline in cognitive function; on the other hand, the cognitive function unchanged. Our results suggest that the treatment with levodopa might prevent a decline in cognitive function in PD.

Entities:  

Keywords:  Parkinson; cognition; dementia; dopamine; levodopa

Year:  2017        PMID: 28695060      PMCID: PMC5498848     

Source DB:  PubMed          Journal:  Am J Neurodegener Dis        ISSN: 2165-591X


  23 in total

1.  The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease.

Authors:  K R Chaudhuri; S Pal; A DiMarco; C Whately-Smith; K Bridgman; R Mathew; F R Pezzela; A Forbes; B Högl; C Trenkwalder
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  A SELF-RATING DEPRESSION SCALE.

Authors:  W W ZUNG
Journal:  Arch Gen Psychiatry       Date:  1965-01

3.  The association of incident dementia with mortality in PD.

Authors:  G Levy; M-X Tang; E D Louis; L J Côté; B Alfaro; H Mejia; Y Stern; K Marder
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.

Authors:  J Kulisevsky; C García-Sánchez; M L Berthier; M Barbanoj; B Pascual-Sedano; A Gironell; A Estévez-González
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

6.  Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

Authors:  D Aarsland; J P Larsen; E Tandberg; K Laake
Journal:  J Am Geriatr Soc       Date:  2000-08       Impact factor: 5.562

7.  Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.

Authors:  Roshan Cools; Elka Stefanova; Roger A Barker; Trevor W Robbins; Adrian M Owen
Journal:  Brain       Date:  2002-03       Impact factor: 13.501

8.  Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time.

Authors:  M D Gjerstad; B Boeve; T Wentzel-Larsen; D Aarsland; J P Larsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-06-08       Impact factor: 10.154

9.  Effects of levodopa on motor sequence learning in Parkinson's disease.

Authors:  A Feigin; M F Ghilardi; M Carbon; C Edwards; M Fukuda; V Dhawan; C Margouleff; C Ghez; D Eidelberg
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

10.  Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.

Authors:  S A Molloy; E N Rowan; J T O'Brien; I G McKeith; K Wesnes; D J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-04       Impact factor: 10.154

View more
  7 in total

1.  Memantine for the patients with mild cognitive impairment in Parkinson's disease: a pharmacological fMRI study.

Authors:  Shoji Kawashima; Noriyuki Matsukawa
Journal:  BMC Neurol       Date:  2022-05-13       Impact factor: 2.903

2.  Slower saccadic reading in Parkinson's disease.

Authors:  Naz Jehangir; Caroline Yizhu Yu; Jeehey Song; Mohammad Ali Shariati; Steven Binder; Jill Beyer; Veronica Santini; Kathleen Poston; Yaping Joyce Liao
Journal:  PLoS One       Date:  2018-01-24       Impact factor: 3.240

Review 3.  A Neuropsychological Rehabilitation Program for Cognitive Impairment in Psychiatric and Neurological Conditions: A Review That Supports Its Efficacy.

Authors:  Ainara Gómez-Gastiasoro; Javier Peña; Naroa Ibarretxe-Bilbao; Olaia Lucas-Jiménez; María Díez-Cirarda; Oiane Rilo; Genoveva Montoya-Murillo; Leire Zubiaurre-Elorza; Natalia Ojeda
Journal:  Behav Neurol       Date:  2019-10-21       Impact factor: 3.342

4.  Effects of daily L-dopa administration on learning and brain structure in older adults undergoing cognitive training: a randomised clinical trial.

Authors:  Alexander V Lebedev; Jonna Nilsson; Joanna Lindström; William Fredborg; Ulrika Akenine; Carolina Hillilä; Pia Andersen; Gabriela Spulber; Elizabeth C M de Lange; Dirk-Jan van den Berg; Miia Kivipelto; Martin Lövdén
Journal:  Sci Rep       Date:  2020-03-23       Impact factor: 4.379

Review 5.  Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control.

Authors:  Luisa Speranza; Umberto di Porzio; Davide Viggiano; Antonio de Donato; Floriana Volpicelli
Journal:  Cells       Date:  2021-03-26       Impact factor: 6.600

Review 6.  The aging immune system in Alzheimer's and Parkinson's diseases.

Authors:  Kelsey S Heavener; Elizabeth M Bradshaw
Journal:  Semin Immunopathol       Date:  2022-05-03       Impact factor: 11.759

7.  Characteristics of Parkinson's Disease in Patients with and without Cognitive Impairment.

Authors:  Julie M Chandler; Radhika Nair; Kevin Biglan; Erin A Ferries; Leanne M Munsie; Tich Changamire; Nick Patel
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.